{"entity":{"id":"azd4360","kind":"drug","name":"AZD4360","aka":[],"tldr":"AZD4360 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.","summary":"AZD4360 is an antibody-drug conjugate developed by AstraZeneca. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: AZD4360 is an antibody-drug conjugate targeting Claudin 18.2, being studied in advanced solid tumours including gastric, gastro-oesophageal junction, biliary tract and pancreatic cancers. ClinicalTrials.gov describes the intervention as: Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma. The largest, NCT06921928, plans to enrol 31 participants (actual) with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD4360","url":"https://clinicaltrials.gov/search?intr=AZD4360"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","cholangiocarcinoma","pancreatic"],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06921928"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["23 Sept 2026: the payload is not stated on any record OnCo reads, so the open drug engine shows AZD4360 under Claudin 18.2 with the payload class not recorded rather than guessing."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"AZD4360 is an antibody-drug conjugate targeting Claudin 18.2, being studied in advanced solid tumours including gastric, gastro-oesophageal junction, biliary tract and pancreatic cancers.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd4360/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct06921928","kind":"trial","name":"Study for AZD4360 in Participants With Advanced Solid Tumours","route":"/trials/nct06921928/"}]}}